tiprankstipranks
AstraZeneca PLC (GB:AZN)
LSE:AZN
UK Market
AZN
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (AZN) Stock News & Sentiment

914 Followers
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
Premium
Ratings
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
20h ago
AZN
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
Premium
Company Announcements
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
5d ago
AZN
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study
Premium
Company Announcements
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study
6d ago
AZN
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating
Premium
Ratings
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating
7d ago
AZN
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates
Premium
Company Announcements
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates
12d ago
AZN
AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
Premium
Company Announcements
AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
12d ago
AZN
AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
Premium
Company Announcements
AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
13d ago
AZN
More GB:AZN News >

AZN News on the Web

GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50%
GuruFocus News
Neutral
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Zacks
Bullish
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
TipRanks News
Bullish
GLP-1 Drugs Move Up The Leaderboard As Twin Epidemics Continue To Balloon
rttnews
Bearish
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
CNBC
Bearish
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
GuruFocus News
Neutral
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside
Proactive Investors
Neutral
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
GB:AZN
Sector Average
Media Buzz
This Week20 articles
Weekly Average23.75 articles
News Sentiment
This Week64%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GB:AZN’s Media Buzz Sentiment?
20 articles about GB:AZN were published this week. In an average week, 23.75 articles are published.
    What is GB:AZN’s weekly average amount of articles?
    In an average week, 23.75 articles about GB:AZN are published.
      What is GB:AZN’s News Sentiment?
      64% of articles about GB:AZN were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week